{"id":148299,"date":"2026-08-22T19:18:38","date_gmt":"2026-08-22T19:18:38","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/148299\/"},"modified":"2026-08-22T19:18:38","modified_gmt":"2026-08-22T19:18:38","slug":"ai-based-augmentation-of-oncology-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/148299\/","title":{"rendered":"AI-based augmentation of oncology clinical trials"},"content":{"rendered":"

Shen, C. et al. Underperformance of contemporary phase III oncology trials and strategies for improvement. J. Natl Compr. Canc Netw. 19, 1072\u20131080 (2021).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhou, Y. et al. Dynamic clinical trial success rates for drugs in the 21st century. Nat. Commun. 16, 9537 (2025).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Olawade, D. B. et al. Artificial intelligence in clinical trials: a comprehensive review of opportunities, challenges, and future directions. Int. J. Med. Inf. 206, 106141 (2026).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lamp, S. J. & Mazza, G. L. Expected vs observed effect sizes for survival endpoints in phase 3 oncology trials. J. Natl Cancer Inst. 117, 1938\u20131941 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Azenkot, T. et al. Artificial intelligence and machine learning innovations to improve design and representativeness in oncology clinical trials. ASCO Educ. Book 45, 3 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Cascini, F. et al. Scoping review of the current landscape of AI-based applications in clinical trials. Front. Public Health 10, 949377 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Shah, P. et al. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digit. Med. 2, 69 (2019).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Saady, M. et al. Implementation of artificial intelligence approaches in oncology clinical trials: a systematic review. Artif. Intell. Med. 161, 103066 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chow, R. et al. Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis. J. Natl Cancer Inst. 115, 365\u2013374 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Benbow, J. H. & Kim, E. S. Harnessing artificial intelligence to transform clinical trials and cancer care: opportunities and challenges. Cancer J. 31, e0796 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhang, K. et al. Artificial intelligence in drug development. Nat. Med. 31, 45\u201359 (2025).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Singh, R. et al. How AI is used in FDA-authorized medical devices: a taxonomy across 1,016 authorizations. NPJ Digit. Med. 8, 388 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kurbegov, D. et al. Recommendations to streamline and standardize clinical trial site feasibility assessments: an ASCO research statement. JCO Oncol. Pract. 17, 41\u201351 (2021).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kirkwood, M. K. et al. State of geographic access to cancer treatment trials in the United States: are studies located where patients live? JCO Oncol. Pract. 21, 427\u2013437 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Afrin, L. B., Oates, J. C. & Kamen, D. L. Improving clinical trial accrual by streamlining the referral process. Int. J. Med. Inf. 84, 15\u201323 (2015).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Stensland, K. D. et al. Adult cancer clinical trials that fail to complete: an epidemic? J. Natl Cancer Inst. 106, 9 (2014).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chen, L. et al. Screening intervention to identify eligible patients and improve accrual to phase II-IV oncology clinical trials. J. Oncol. Pract. 9, e174\u2013e181 (2013).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hardy-Werbin, M., Gonz\u00e1lez Gallardo, S., Garc\u00eda-Mosquera, J. J. & Arriola Aperribay, E. Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities. ESMO Real World Data Digital Oncol. 2, 100006 (2023).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mehari, M. et al. Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning. Sci. Adv. 11, eadt 5708 (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tien, H. D., Masquelier, A., Lee, N. E. & Crowther, J. Deep learning-based prediction of clinical trial enrollment with uncertainty estimates. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2507.23607<\/a> (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chakraborty, S. TOPSIS and modified TOPSIS: a comparative analysis. Decis. Analytics J. 2, 100021 (2022).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hulstaert, L., Twick, I., Sarsour, K. & Verstraete, H. Enhancing site selection strategies in clinical trial recruitment using real-world data modeling. PLoS One 19, e0300109 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Fadiel, A., Eichenbaum, K. D., Abbasi, M., Lee, N. K. & Odunsi, K. Utilizing geospatial artificial intelligence to map cancer disparities across health regions. Sci. Rep. 14, 7693 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Liu, R. et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature 592, 629\u2013633 (2021).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jreich, R., Zhang, H., Meng, Z. & Wang, F. Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials. J. Comp. Eff. Res. 13, e230164 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, Z., Xiao, C. & Sun, J. Autotrial: prompting language models for clinical trial design. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2305.11366<\/a> (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Unger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M. & Fleury, M. E. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J. Natl Cancer Inst. 111, 245\u2013255 (2019).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kim, E. S. et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J. Clin. Oncol. 35, 3737\u20133744 (2017).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Andrade, C. Target trial emulation: a concept simply explained. J. Clin. Psychiatry 86, 1 (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Cashin, A. G. et al. Transparent reporting of observational studies emulating a target trial-the TARGET statement. JAMA 334, 1084\u20131093 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Liddicoat, J. E. et al. A policy framework for leveraging generative AI to address enduring challenges in clinical trials. NPJ Digital Med. 8, 33 (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Getz, K. A. et al. The impact of protocol amendments on clinical trial performance and cost. Ther. Innov. Regul. Sci. 50, 436\u2013441 (2016).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Maleki, M. & Ghahari, S. Clinical trials protocol authoring using LLMs. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2404.05044<\/a> (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Haoyang, L. et al. TrialGenie: empowering clinical trial design with agentic intelligence and real-world data. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.04.17.25326033<\/a> (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

O\u2019Dwyer, P. J. et al. The NCI-MATCH trial: lessons for precision oncology. Nat. Med. 29, 1349\u20131357 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Clark, A. S. et al. Neoadjuvant T-DM1\/pertuzumab and paclitaxel\/trastuzumab\/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat. Commun. 12, 6428 (2021).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Halabi, S., Choi, T., Garrett-Mayer, E., Schilsky, R. L. & Trippa, L. Incorporating data from multiple ongoing trials for Bayesian two-stage phase II single-arm studies. Clin. Trials 22, 667\u2013675 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mangat, P. K. et al. Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis. Oncol. 2, 1\u201314 https:\/\/doi.org\/10.1200\/PO.18.00122<\/a> (2018).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Halabi, S. & Niedzwiecki, D. Advancing precision oncology through biomarker-driven trials: theory vs. practice. Chance 32, 23\u201331 (2019).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62\u201370 (2017).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Markey, N., El-Mansouri, I., Rensonnet, G., van Langen, C. & Meier, C. From RAGs to riches: utilizing large language models to write documents for clinical trials. Clin. Trials 22, 626\u2013631 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). M15 General Principles for Model-Informed Drug Development, FDA MIDD https:\/\/www.fda.gov\/media\/184747\/download<\/a> (2024).<\/p>\n

Arai, R. J. et al. Personalizing precision oncology clinical trials in latin america: an expert panel on challenges and opportunities. Oncologist 24, e709\u2013e719 (2019).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hashmi, M. et al. Single-arm oncology trials and the nature of external controls arms. J. Comp. Eff. Res. 10, 1052\u20131066 (2021).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Eckardt, J. N. et al. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence. NPJ Digit. Med. 7, 76 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tan, K. et al. Emulating control arms for cancer clinical trials using external cohorts created from electronic health record-derived real-world data. Clin. Pharmacol. Ther. 111, 168\u2013178 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Loiseau, N. et al. External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning. BMC Med. Res. Methodol. 22, 335 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sadique, Z. et al. A machine-learning approach for estimating subgroup- and individual-level treatment effects: an illustration using the 65 trial. Med. Decis. Mak. 42, 923\u2013936 (2022).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Rippin, G. et al. A review of causal inference for external comparator arm studies. Drug. Saf. 45, 815\u2013837 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Eckardt, J. N. et al. Artificial intelligence-generated synthetic data for cancer research and clinical trials. Nat. Rev. Cancer 26, 351\u2013363 (2026).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Elvatun, S., Knoors, D., Brant, S., Jonasson, C. & Nyg\u00e5rd, J. F. Synthetic data as external control arms in scarce single-arm clinical trials. PLoS Digit. Health 4, e0000581 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sarkar, A. R. et al. De-identification is not enough: a comparison between de-identified and synthetic clinical notes. Sci. Rep. 14, 29669 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Arondekar, B. et al. Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015-2020. Clin. Cancer Res. 28, 27\u201335 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Farah, E., Kenney, M., Warkentin, M. T., Cheung, W. Y. & Brenner, D. R. Examining external control arms in oncology: a scoping review of applications to date. Cancer Med. 13, e7447 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wedam, S. et al. FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clin. Cancer Res. 26, 1208\u20131212 (2020).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Rambaldi, A. et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer 126, 304\u2013310 (2020).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

U.S. Food and Drug Administration. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products<\/a> (2023).<\/p>\n

Knapen, D. G., van Kruchten, M., de Groot, D. J. A., Broekman, K. E. & Fehrmann, R. S. N. Artificial intelligence for clinical trial design, conduct, and analysis: a narrative review,. ESMO Real World Data Digital Oncol. 11, 100682 (2026).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, Z. et al. PyTrial: machine learning software and benchmark for clinical trial applications. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2306.04018<\/a> (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Fu, T., Huang, K., Xiao, C., Glass, L. M. & Sun, J. HINT: hierarchical interaction network for clinical-trial-outcome predictions. Patterns 3, 100445 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, Z., Xiao, C. & Sun, J. SPOT: sequential predictive modeling of clinical trial outcome with meta-learning. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2304.05352<\/a> (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Aliper, A. et al. Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence. Clin. Pharmacol. Ther. 114, 972\u2013980 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Unger, J. M., Shulman, L. N., Facktor, M. A., Nelson, H. & Fleury, M. E. National estimates of the participation of patients with cancer in clinical research studies based on commission on cancer accreditation data. J. Clin. Oncol. 42, 2139\u20132148 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gueguen, L., Olgiati, L., Brutti-Mairesse, C., Sans, A., Le Texier, V. & Verlingue, L. A prospective pragmatic evaluation of automatic trial matching tools in a molecular tumor board. NPJ Precis. Oncol. 9, 28 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Roberts, K., Demner-Fushman, D., Voorhees, E. M., Bedrick, S., Hersh, W. R. Overview of the TREC 2022 clinical trials track. Proceedings of the Thirty-First Text REtrieval Conference (TREC 2022), NIST Special Publication 500\u2013338 (TREC, 2022).<\/p>\n

Jullien, M., Valentino, M., Frost, H., O\u2019Regan, P., Landers, D. & Freitas, A. NLI4CT: multi-evidence natural language inference for clinical trial reports. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2305.03598<\/a> (2023).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jin, Q. et al. Matching patients to clinical trials with large language models. Nat. Commun. 15, 9074 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Loaiza-Bonilla, A. et al. Transforming oncology clinical trial matching through neuro-symbolic, multi-agent AI and an oncology-specific knowledge graph: a prospective evaluation in 3804 patients. ESMO Real World Data Digital Oncol. 12, 100706 (2026).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Beck, J. T. et al. Artificial intelligence tool for optimizing eligibility screening for clinical trials in a large community cancer center. JCO Clin. Cancer Inf. 4, 50\u201359 (2020).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bickell, N. A. et al. Implementation of a rule-based algorithm to find patients eligible for cancer clinical trials. JAMIA Open 7, ooae131 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Rosenthal, J. T. et al. AI-assisted workflow enables rapid, high-fidelity breast cancer clinical trial eligibility prescreening. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2511.05696<\/a> (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Parikh, R. B. et al. Human-AI teaming to improve accuracy and efficiency of eligibility criteria prescreening for oncology trials: a randomized evaluation trial using retrospective electronic health records. Nat. Commun. 17, 2306 (2026).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kehl, K. L. et al. Identifying oncology clinical trial candidates using artificial intelligence predictions of treatment change: a pilot implementation study. JCO Precis. Oncol. 8, e2300507 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Oo, V. F. et al. 20P Prospective pilot study of AI-assisted clinical trial matching system. ESMO Open 10, 105366 (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jiby, J. T. et al. A prospective study comparing AI-based clinical trial eligibility screening with traditional EMR-based screening. J. Clin. Oncol. 42, e13636 (2024).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mazor, T. et al. Clinical trial notifications triggered by artificial intelligence\u2013detected cancer progression: a randomized trial. JAMA Netw. Open 8, e252013 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Altreuter, J. MatchMiner-AI: an open-source solution for cancer clinical trial matching. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2412.17228<\/a> (2024).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

La Rosa, A. et al. \u2018The truth is, we must miss some\u2019: a qualitative study of the patient eligibility screening process, and automation perspectives, for cancer clinical trials. Cancer Med. 13, e70466 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Haddad, T. et al. Accuracy of an artificial intelligence system for cancer clinical trial eligibility screening: retrospective pilot study. JMIR Med. Inform. 9, e27767 (2021).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

von Itzstein, M. S. et al. Application of information technology to clinical trial evaluation and enrollment: a review. JAMA Oncol. 7, 1559\u20131566 (2021).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gong, G. et al. Clinical trial patient matching: a real-time, common data model and artificial intelligence-driven system for semiautomated patient prescreening in cancer clinical trials. JCO Clin. Cancer Inf. 10, e2500262 (2026).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Liang, F., Peng, L., Wu, Z., Giamas, G. & Stebbing, J. Design and reporting of phase III oncology trials with prospective biomarker validation. J. Natl Cancer Inst. 115, 174\u2013180 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Almuradova, E. et al. From dose-finding to dose-optimization in early-phase oncology clinical trials. Cancer Treat. Rev. 136, 102906 (2025).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jiang, Z., Sun, W., Du, R. & Yang, R. A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials. Clin. Transl. Oncol. 26, 2116\u20132125 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yuan, Y. et al. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin. Cancer Res. 22, 4291\u20134301 (2016).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Thall, P. F. et al. Novel clinical trial designs with dose optimization to improve long-term outcomes. Clin. Cancer Res. 29, 4549\u20134554 (2023).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yuan, S., Huang, Z., Liu, J. & Ji, Y. Pharmacometrics-enabled DOse OPtimization (PEDOOP) for seamless phase I-II trials in oncology. J. Biopharm. Stat. 36, 59\u201378 (2026).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Teplytska, O. et al. Machine learning methods for precision dosing in anticancer drug therapy: a scoping review. Clin. Pharmacokinet. 63, 1221\u20131237 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

De Carlo, A., Tosca, E. M., Fantozzi, M. & Magni, P. Reinforcement learning and PK-PD models integration to personalize the adaptive dosing protocol of erdafitinib in patients with metastatic urothelial carcinoma. Clin. Pharmacol. Ther. 115, 825\u2013838 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lee, K. J. & Ji, Y. Precision dose-finding design for phase I oncology trials by integrating pharmacology data. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2509.05120<\/a> (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Fang, C., Zhou, P., Zhang, X., He, Y. & Yang, Q. Artificial intelligence in oncology drug development and management: a precision medicine perspective. Front. Oncol. 15, 1609827 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Blasiak, A. et al. Personalized dose selection platform for patients with solid tumors in the precise curate. AI feasibility trial. NPJ Precis. Oncol. 9, 49 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hauck, C. L., Kelechi, T. J., Cartmell, K. B. & Mueller, M. Trial-level factors affecting accrual and completion of oncology clinical trials: a systematic review. Contemp. Clin. Trials Commun. 24, 100843 (2021).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Pfeffer, M., Deneris, M., Shelley, A., Salcuni, P. & Altomare, I. Utility of automated data transfer for cancer clinical trials and considerations for implementation. ESMO Real World Data Digit. Oncol. 7, 100112. https:\/\/doi.org\/10.1016\/j.esmorw.2025.100112<\/a> (2025).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gauthier, M. P. et al. Automating access to real-world evidence. JTO Clin. Res. Rep. 3, 100340 (2022).<\/p>\n

PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Miller, T. P. et al. Automated electronic health record data extraction and curation using ExtractEHR. JCO Clin. Cancer Inf. 8, e2400100 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Huang, F. et al. Advancing the use of longitudinal electronic health records: tutorial for uncovering real-world evidence in chronic disease outcomes. J. Med. Internet Res. 27, e71873 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Cappello, G. et al. A European Society of Oncologic Imaging (ESOI) survey on the radiological assessment of response to oncologic treatments in clinical practice. Insights Imaging 14, 220 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Xu, W., Gu, B., Lotter, W. E. & Kehl, K. L. Extraction and imputation of Eastern Cooperative Oncology Group performance status from unstructured oncology notes using language models. JCO Clin. Cancer Inf. 8, e2300269 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Jung, E., Jain, H., Sinha, A. P. & Gaudioso, C. Building a specialized lexicon for breast cancer clinical trial subject eligibility analysis. Health Inform. J. 27, 1460458221989392 (2021).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Inan, O. T. et al. Digitizing clinical trials. NPJ Digital Med. 3, 101 (2020).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sim, J. et al. Natural language processing with machine learning methods to analyze unstructured patient-reported outcomes derived from electronic health records: a systematic review. Artif. Intell. Med. 146, 102701 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Aiyegbusi, O. L. et al. Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection. Nat. Commun. 13, 6026 (2022).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chow, R. et al. The use of wearable devices in oncology patients: a systematic review. Oncologist 29, e419\u2013e430 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Acosta, J. N., Falcone, G. J., Rajpurkar, P. & Topol, E. J. Multimodal biomedical AI. Nat. Med. 28, 1773\u20131784 (2022).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Piccinin, C. et al. Flexibility in patient-reported outcome and health-related quality of life measurement: the EORTC Quality of Life Group measurement strategy. Eur. J. Cancer 220, 115392 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Llave, K. et al. Meaningful differences and changes for five patient-reported outcomes measurement information system domains in a large cohort of patients with cancer. Cancer 132, e70219 (2026).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Piccinin, C. et al. Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group. Lancet Oncol. 24, e86\u2013e95 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Phipps, J. et al. Early adverse physiological event detection using commercial wearables: challenges and opportunities. NPJ Digital Med. 7, 136 (2024).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Scheid, M. R., Friedmann, B., Oppenheim, M., Hirsch, J. S. & Zanos, T. P. Development and validation of a clinical wearable deep learning based continuous inhospital deterioration prediction model. Nat. Commun. 16, 9513 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Brouwer, C. G. et al. Machine learning-based prediction of clinical outcomes in patients with cancer receiving systemic treatment using step count data measured with smartphones. JCO Clin. Cancer Inf. 9, e2500023 (2025).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Friesner, I. D. et al. Machine learning-based prediction of hospitalization during chemoradiotherapy with daily step counts. JAMA Oncol. 10, 642\u2013647 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Grant, R. C. et al. Machine learning-based early warning systems for acute care utilization during systemic therapy for cancer. J. Natl Compr. Canc Netw. 21, 1029\u20131037 (2023).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Giangregorio, C. et al. Automatic cough analysis for non-small cell lung cancer detection. Annu Int Conf IEEE Eng Med Biol Soc. https:\/\/doi.org\/10.1109\/EMBC58623.2025.11254401<\/a> (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Mooney, K. et al. Essential components of an electronic patient-reported symptom monitoring and management system: a randomized clinical trial. JAMA Netw. Open 7, e2433153 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Basch, E. et al. Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial. JAMA 327, 2413\u20132422 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Norwood, P., Davidian, M. & Laber, E. Adaptive randomization methods for sequential multiple assignment randomized trials (SMARTS) via Thompson sampling. Biometrics 3, 4 (2024).<\/p>\n


\n Google Scholar<\/a>\u00a0\n <\/p>\n

Yazzourh, S., Savy, N., Saint-Pierre, P. & Kosorok, M. R. Medical knowledge integration into reinforcement learning algorithms for dynamic treatment regimes. Int. Stat. Rev. https:\/\/doi.org\/10.1111\/insr.12617<\/a> (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Song, Y. & Wang, L. Multiobjective tree-based reinforcement learning for estimating tolerant dynamic treatment regimes. Biometrics 80, 1 (2024).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, J. & Tiwari, R. Optimal dose selection in phase I\/II dose finding trial with contextual bandits: a case study and practical recommendations. J. Biopharm. Stat. 36, 107\u2013133 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zhao, Y. et al. DOD-BART: machine learning-based dose optimization design incorporating patient-level prognostic factors via Bayesian additive regression trees. J. Biopharm. Stat. https:\/\/doi.org\/10.1080\/10543406.2024.2429463<\/a> (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gallagher, K. et al. Mathematical model-driven deep learning enables personalized adaptive therapy. Cancer Res. 84, 1929\u20131941 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Ravi, R. & Kesari, H. V. Novel study designs in precision medicine \u2014 basket, umbrella and platform trials. Curr. Rev. Clin. Exp. Pharmacol. 17, 114\u2013121 (2022).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

European Medicines Agency. ICH E20 Adaptive Designs for Clinical Trials \u2014 Scientific Guideline https:\/\/www.ema.europa.eu\/en\/ich-e20-adaptive-designs-clinical-trials-scientific-guideline<\/a> (2025).<\/p>\n

US Food and Drug Administration. Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry<\/a> (2019).<\/p>\n

Murthy, V. H., Krumholz, H. M. & Gross, C. P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291, 2720\u20132726 (2024).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Karim, S. et al. Generalisability of common oncology clinical trial eligibility criteria in the real world. Clin. Oncol. 31, e160\u2013e166 (2019).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Orcutt, X. et al. Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. Nat. Med. 31, 457\u2013465 (2025).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Westreich, D., Edwards, J. K., Lesko, C. R., Stuart, E. & Cole, S. R. Transportability of trial results using inverse odds of sampling weights. Am. J. Epidemiol. 186, 1010\u20131014 (2017).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Sad\u00e9e, C. et al. Medical digital twins: enabling precision medicine and medical artificial intelligence. Lancet Digital Health 7, 100864 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Vall\u00e9e, A. Digital twin for healthcare systems. Front. Digit. Health 5, 1253050 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Asghar, U. S. & Chung, C. Application of digital twins for personalized oncology. Nat. Rev. Cancer 25, 823\u2013825 (2025).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Susilo, M. E. et al. Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a phase I study of bispecific antibody, mosunetuzumab, in NHL. Clin. Transl. Sci. 16, 1134\u20131148 (2023).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wang, H. et al. From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling. NPJ Digit. Med. 7, 189 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lammert, J. et al. Large language models-enabled digital twins for precision medicine in rare gynecological tumors. NPJ Digit. Med. 8, 420 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bouriga, R. et al. Advances and critical aspects in cancer treatment development using digital twins. Brief. Bioinforma. 26, bbaf237 (2025).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Zech, P. et al. Model-based digital twin engineering: insights, challenges, and future directions. Softw. Syst. Model. https:\/\/doi.org\/10.1007\/s10270-026-01368-8<\/a> (2026).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Laubenbacher, R. et al. Digital twins in medicine. Nat. Comput. Sci. 4, 184\u2013191 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Hern\u00e1n, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758\u2013764 (2016).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tikhomirov, L. et al. A scoping review of silent trials for medical artificial intelligence. Nat. Health 1, 532\u2013554 (2026).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kwong, J. C. C. et al. The silent trial – the bridge between bench-to-bedside clinical AI applications. Front. Digit. Health 4, 929508 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Rosenthal, J. T., Beecy, A. & Sabuncu, M. R. Rethinking clinical trials for medical AI with dynamic deployments of adaptive systems. NPJ Digit. Med. 8, 252 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Verhagen, C. T. et al. Understanding unrealized trial enrollments following patient-to-trial matching with large language models. Surgery 191, 109915 (2026).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Westerman, G. et al. Enterprise-level AI screening for oncology trials: improving patient identification with OncoLLM. J. Clin. Oncol. 43, e13706 (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Halabi, S. & Kelly, W. K. The changing landscape of clinical research and trials. In: Oncology Clinical Trials: Successful Design, Conduct, and Analysis 2 ed (eds Kelly, W. K. & Halabi, S.) 1\u201311 (Springer Publishing Company, 2018).<\/p>\n

Perni, S. et al. Assessment of use, specificity, and readability of written clinical informed consent forms for patients with cancer undergoing radiotherapy. JAMA Oncol. 5, e190260 (2019).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Wu, D. T. et al. Assessing the readability of clinicaltrials.gev. J. Am. Med. Inform. Assoc. 23, 269\u2013275 (2016).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Aristizabal, P. et al. Social determinants of health and informed consent comprehension for pediatric cancer clinical trials. JAMA Netw. Open 6, e2346858 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Goodson, N. et al. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. NPJ Digit. Med. 5, 58 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Aiyegbusi, O. L. et al. Recommendations to promote equity, diversity and inclusion in decentralized clinical trials. Nat. Med. 30, 3075\u20133084 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Cohen, E., Byrom, B., Becher, A., J\u00f6rnt\u00e9n-Karlsson, M. & Mackenzie, A. K. Comparative effectiveness of econsent: systematic review. J. Med. Internet Res. 25, e43883 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Politi, M. C. et al. Decision aids can support cancer clinical trials decisions: results of a randomized trial. Oncologist 21, 1461\u20131470 (2016).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Gao, M. et al. The use of large language models to enhance cancer clinical trial educational materials. JNCI Cancer Spectr. 9, pkaf021 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lee, P., Bubeck, S. & Petro, J. Benefits, limits, and risks of GPT-4 as an AI chatbot for medicine. N. Engl. J. Med. 388, 1233\u20131239 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Robinson, K. A., Dennison, C. R., Wayman, D. M., Pronovost, P. J. & Needham, D. M. Systematic review identifies number of strategies important for retaining study participants. J. Clin. Epidemiol. 60, 757 (2007).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Cicin, F. N. & Cicin, I. Integrating mhealth innovations into decentralized oncology trials. J. Med. Syst. 49, 103 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Rajkomar, A., Hardt, M., Howell, M. D., Corrado, G. & Chin, M. H. Ensuring fairness in machine learning to advance health equity. Ann. Intern. Med. 169, 866\u2013872 (2018).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Obermeyer, Z. et al. Dissecting racial bias in an algorithm used to manage the health of populations. Science 366, 447\u2013453 (2019).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Chinta, S. V. et al. AI-driven healthcare: a review on ensuring fairness and mitigating bias. PLoS Digital Health 4, e0000864 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Dankwa-Mullan, I. & Weeraratne, D. Artificial intelligence and machine learning technologies in cancer care: addressing disparities, bias, and data diversity. Cancer Discov. 12, 1423\u20131427 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

DeCamp, M. & Lindvall, C. Latent bias and the implementation of artificial intelligence in medicine. J. Am. Med. Inf. Assoc. 27, 2020\u20132023 (2020).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lawson McLean, A. & Hristidis, V. Evidence-based analysis of ai chatbots in oncology patient education: implications for trust, perceived realness, and misinformation management. J. Canc Educ. 40, 482\u2013489 (2025).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Lekadir, K. et al. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ 388, e081554 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Schwabe, D., Becker, K., Seyferth, M., Kla\u00df, A. & Schaeffter, T. The METRIC-framework for assessing data quality for trustworthy AI in medicine: a systematic review. NPJ Digit. Med. 7, 203 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Koch, L. M., Baumgartner, C. F. & Berens, P. Distribution shift detection for the postmarket surveillance of medical AI algorithms: a retrospective simulation study. NPJ Digit. Med. 7, 120 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Subasri, V. et al. Detecting and remediating harmful data shifts for the responsible deployment of clinical AI models. JAMA Netw. Open 8, e2513685 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Kore, A. et al. Empirical data drift detection experiments on real-world medical imaging data. Nat. Commun. 15, 1887 (2024).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Feng, J. et al. Clinical artificial intelligence quality improvement: towards continual monitoring and updating of AI algorithms in healthcare. NPJ Digit. Med. 5, 66 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Nazir, A. et al. LangTest: a comprehensive evaluation library for custom LLM and NLP models. Softw. Impacts 19, 100619 (2024).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tam, T. Y. C. et al. A framework for human evaluation of large language models in healthcare derived from literature review. NPJ Digital Med. 7, 258 (2024).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Bommasani, R., Liang, P. & Lee, T. Holistic evaluation of language models. Ann. N. Y. Acad. Sci. 1525, 140\u2013146 (2023).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Rivera, S. C. et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nat. Med. 26, 1351\u20131363 (2020).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Liu, X., Cruz Rivera, S., Moher, D., Calvert, M. J. & Denniston, A. K. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat. Med. 26, 1364\u20131374 (2020).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

European Commission. Ethics Guidelines for Trustworthy AI (European Commission, 2019).<\/p>\n

European Medicines Agency. Reflection Paper on the Use of Artificial Intelligence in the Lifecycle of Medicines https:\/\/www.ema.europa.eu\/en\/news\/reflection-paper-use-artificial-intelligence-lifecycle-medicines<\/a> (2023).<\/p>\n

Vasey, B. et al. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat. Med. 28, 924\u2013933 (2022).<\/p>\n

Article<\/a>\u00a0
\n CAS<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Collins, G. S. et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ 385, e078378 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Moons, K. G. M. et al. PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ 388, e082505 (2025).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

U.S. Food and Drug Administration. Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-making for Drug and Biological Products. Draft Guidance for Industry (FDA, 2025).<\/p>\n

U.S. Food and Drug Administration, Health Canada & the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency. Good Machine Learning Practice for Medical Device Development: Guiding Principles https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medical-devices\/good-machine-learning-practice-medical-device-development.html<\/a> (2021).<\/p>\n

Pharmaceuticals and Medical Devices Agency (Japan). Report on AI-based Software as a Medical Device (SaMD) https:\/\/www.pmda.go.jp\/files\/000266100.pdf<\/a> (2023).<\/p>\n

Han, Y., Ceross, A. & Bergmann, J. Regulatory frameworks for ai-enabled medical device software in china: comparative analysis and review of implications for global manufacturer. JMIR AI 3, e46871 (2024).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Tan, R. K. J. et al. Digital approaches to enhancing community engagement in clinical trials. NPJ Digit. Med. 5, 37 (2022).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Askin, S., Burkhalter, D., Calado, G. & El Dakrouni, S. Artificial intelligence applied to clinical trials: opportunities and challenges. Health Technol. 13, 203\u2013213 (2023).<\/p>\n

Article<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n

Prelaj, A. et al. APOLLO11:a bio-data-driven model for clinical and translational research in lung cancer. NPJ Precis. Oncol. 10, 96 (2026).<\/p>\n

Article<\/a>\u00a0
\n PubMed<\/a>\u00a0
\n PubMed Central<\/a>\u00a0
\n
\n Google Scholar<\/a>\u00a0\n <\/p>\n","protected":false},"excerpt":{"rendered":"Shen, C. et al. Underperformance of contemporary phase III oncology trials and strategies for improvement. J. Natl Compr.…\n","protected":false},"author":2,"featured_media":148300,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[72719,24,25,1940,28569,375,617,50,21053,5813],"class_list":["post-148299","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ai","tag-adaptive-clinical-trial","tag-ai","tag-artificial-intelligence","tag-cancer","tag-clinical-trial-design","tag-clinical-trials","tag-general","tag-machine-learning","tag-medicine-public-health","tag-oncology"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/148299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=148299"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/148299\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/148300"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=148299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=148299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=148299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}